Core Viewpoint - The company has received a drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Powder from the National Medical Products Administration, which will enable it to accelerate mass production and market launch of the new product [1] Group 1 - The registration certificate allows the company to expand its product matrix and optimize its product structure layout [1] - The company aims to leverage its brand resource advantages to enhance market competitiveness [1]